Page 49 - ESGO - Vulvar cancer - Complete report_fxd2

16 Acronyms and abbreviations DOT dead of treatment
DSS disease specific survival
5-FU 5-fluorouracil ECOG Eastern cooperative oncology group
99mTc technectium-99m ESGO European society of gynaecological
ACPG Alberta clinical practice guidelines oncology
AGDH Australian government department of health ESMO European society of medical Oncology
AHRQ agency for healthcare research and quality FIGO international federation of gynecology and
AquAS agència de qualitat i avaluació sanitàries de obstetrics
Catalunya FN false negative
ASCO American society of clinical oncology FNA fine-needle aspiration
AUC area under the curve FNAC fine-needle aspiration cytology
BCCA British Columbia cancer agency FP false positive
BID twice a day GIN guidelines international network
Bleo bleomycin GOC gynaecological oncology centre
CADTH Canadian agency for drugs and GOG gynecologic oncology group
technologies in health GROINSS-V Groningen international study on
Carbo carboplatin sentinel nodes in vulvar cancer
CCO cancer care Ontario H&E haematoxylin and eosin
CCNU lomustine HAS haute autorité de santé
cCR clinical complete response HR hazard ratio
CEPO comité de l’évolution des pratiques en IHC immunohistochemistry
oncologie ILND inguinal lymph node dissection
CI confidence interval IMRT intensity-modulated radiation therapy
CisP cisplatin INAHTA international network of agencies for
CoCanCPG coordination of cancer clinical practice health technology assessment
guidelines in Europe INCa institut national du cancer
COMPAQ-HPST coordination pour la mesure de la INESSS institut national d’excellence en santé et en
performance et l’amélioration de la qualité, hôpital, services sociaux
patient, sécurité, territoire IPTW inverse probability of treatment weighting
CR complete response KCE centre fédéral d’expertise des soins de santé
CT computed tomography LAVC locally advanced vulvar cancer
Cyclo cyclophosphamide
DICD dead of intercurrent disease
DOD dead of disease

 VULVAR CANCER - GUIDELINES 
49